New agents in the treatment of acute lymphocytic leukaemia

Deborah A. Thomas, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

The overall prognosis of adult patients with acute lymphocytic leukaemia (ALL) has improved significantly over the past few decades. Combined modality strategies (e.g. chemotherapy used with targeted therapies such as monoclonal antibodies or tyrosine kinase inhibitors) may improve long-term disease-free survival. Still, most patients succumb to complications of disease progression, with current long-term disease-free survival rates of 30-45% overall. Thus, either new strategies or refinements of old ones are needed to improve the long-term prognosis. An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)771-790
Number of pages20
JournalBest Practice and Research: Clinical Haematology
Volume15
Issue number4
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Chemotherapy
Biological Factors
Protein-Tyrosine Kinases
Disease Progression
Therapeutics
Survival Rate
Monoclonal Antibodies
Drug Therapy

Keywords

  • Acute lymphocytic leukaemia
  • Drug resistance
  • Novel agents

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

New agents in the treatment of acute lymphocytic leukaemia. / Thomas, Deborah A.; Cortes, Jorge; Kantarjian, Hagop M.

In: Best Practice and Research: Clinical Haematology, Vol. 15, No. 4, 01.01.2002, p. 771-790.

Research output: Contribution to journalReview article

Thomas, Deborah A. ; Cortes, Jorge ; Kantarjian, Hagop M. / New agents in the treatment of acute lymphocytic leukaemia. In: Best Practice and Research: Clinical Haematology. 2002 ; Vol. 15, No. 4. pp. 771-790.
@article{da5a44e361d345d79a2c9e95ff7247fc,
title = "New agents in the treatment of acute lymphocytic leukaemia",
abstract = "The overall prognosis of adult patients with acute lymphocytic leukaemia (ALL) has improved significantly over the past few decades. Combined modality strategies (e.g. chemotherapy used with targeted therapies such as monoclonal antibodies or tyrosine kinase inhibitors) may improve long-term disease-free survival. Still, most patients succumb to complications of disease progression, with current long-term disease-free survival rates of 30-45{\%} overall. Thus, either new strategies or refinements of old ones are needed to improve the long-term prognosis. An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL.",
keywords = "Acute lymphocytic leukaemia, Drug resistance, Novel agents",
author = "Thomas, {Deborah A.} and Jorge Cortes and Kantarjian, {Hagop M.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1053/beha.2003.0234",
language = "English (US)",
volume = "15",
pages = "771--790",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - New agents in the treatment of acute lymphocytic leukaemia

AU - Thomas, Deborah A.

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The overall prognosis of adult patients with acute lymphocytic leukaemia (ALL) has improved significantly over the past few decades. Combined modality strategies (e.g. chemotherapy used with targeted therapies such as monoclonal antibodies or tyrosine kinase inhibitors) may improve long-term disease-free survival. Still, most patients succumb to complications of disease progression, with current long-term disease-free survival rates of 30-45% overall. Thus, either new strategies or refinements of old ones are needed to improve the long-term prognosis. An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL.

AB - The overall prognosis of adult patients with acute lymphocytic leukaemia (ALL) has improved significantly over the past few decades. Combined modality strategies (e.g. chemotherapy used with targeted therapies such as monoclonal antibodies or tyrosine kinase inhibitors) may improve long-term disease-free survival. Still, most patients succumb to complications of disease progression, with current long-term disease-free survival rates of 30-45% overall. Thus, either new strategies or refinements of old ones are needed to improve the long-term prognosis. An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL.

KW - Acute lymphocytic leukaemia

KW - Drug resistance

KW - Novel agents

UR - http://www.scopus.com/inward/record.url?scp=0036955496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036955496&partnerID=8YFLogxK

U2 - 10.1053/beha.2003.0234

DO - 10.1053/beha.2003.0234

M3 - Review article

C2 - 12617876

AN - SCOPUS:0036955496

VL - 15

SP - 771

EP - 790

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4

ER -